CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia.
Ione O C WoollacottImogen J SwiftAitana Sogorb-EsteveCarolin HellerKathryn KnowlesArabella BouziguesLucy L RussellGeorgia PeakmanCaroline V GreavesRhian ConveryAmanda HeslegraveJames B RoweBarbara BorroniDaniela GalimbertiPietro TiraboschiMario MasellisMaria Carmela TartagliaElizabeth C FingerJohn C van SwietenHarro SeelaarLize JiskootSandro SorbiChris R ButlerCaroline GraffAlexander GerhardRobert Jr LaforceRaquel Sanchez-ValleAlexandre de MendonçaFermin MorenoMatthis SynofzikRik VandenbergheSimon DucharmeIsabelle Le BerJohannes LevinMarkus OttoFlorence PasquierIsabel SantanaHenrik ZetterbergJonathan Daniel Rohrernull nullPublished in: Annals of clinical and translational neurology (2022)
Although chitotriosidase concentrations in GRN mutation carriers were the only significantly raised glia-derived biomarker as a group, a subset of mutation carriers in all three groups, particularly for chitotriosidase and TREM2, had elevated concentrations. Further work is required to understand the variability in concentrations and the extent of neuroinflammation across the genetic forms of FTD. However, the current findings suggest limited utility of these measures in forthcoming trials.